These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30898592)

  • 41. Hypogonadism and metabolic syndrome.
    Corona G; Rastrelli G; Morelli A; Vignozzi L; Mannucci E; Maggi M
    J Endocrinol Invest; 2011; 34(7):557-67. PubMed ID: 21720206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Metabolically Healthy Obesity in Patients with Andrological Problems.
    Lotti F; Rastrelli G; Maseroli E; Cipriani S; Guaraldi F; Krausz C; Reisman Y; Sforza A; Maggi M; Corona G
    J Sex Med; 2019 Jun; 16(6):821-832. PubMed ID: 30962157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
    Luo J; Xu L; Li J; Zhao S
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases.
    Corona G; Mannucci E; Forti G; Maggi M
    Int J Androl; 2009 Dec; 32(6):587-98. PubMed ID: 19226407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women.
    Lee JY; Shin DW; Oh JW; Kim W; Joo SK; Jeon MJ; Kim SM; Yun JM; Son KY; Park JH; Cho B; Lee SM
    PLoS One; 2017; 12(8):e0182708. PubMed ID: 28854246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood.
    Du S; Wang C; Jiang W; Li C; Li Y; Feng R; Sun C
    Diabetes Res Clin Pract; 2016 Jun; 116():183-91. PubMed ID: 27321334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between sexual dysfunction and psychological burden in men with infertility: a large observational study in China.
    Gao J; Zhang X; Su P; Liu J; Shi K; Hao Z; Zhou J; Liang C
    J Sex Med; 2013 Aug; 10(8):1935-42. PubMed ID: 23692444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome.
    Bae JC; Kim SK; Han JM; Kwon S; Lee DY; Kim J; Park SE; Park CY; Lee WY; Oh KW; Park SW; Rhee EJ
    Diabetes Res Clin Pract; 2017 Jul; 129():136-143. PubMed ID: 28527304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
    Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of noninvasive scoring systems for the prediction of nonalcoholic fatty liver disease in metabolic syndrome patients.
    Saokaew S; Kositamongkol C; Charatcharoenwitthaya P; Srivanichakorn W; Washirasaksiri C; Chaiyakunapruk N; Phisalprapa P
    Medicine (Baltimore); 2020 Dec; 99(50):e23619. PubMed ID: 33327335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men.
    Ozturk K; Uygun A; Guler AK; Demirci H; Ozdemir C; Cakir M; Sakin YS; Turker T; Sari S; Demirbas S; Karslıoğlu Y; Saglam M
    Atherosclerosis; 2015 Jun; 240(2):380-6. PubMed ID: 25875390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
    Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.
    Díaz LA; Arab JP; Louvet A; Bataller R; Arrese M
    Nat Rev Gastroenterol Hepatol; 2023 Dec; 20(12):764-783. PubMed ID: 37582985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis.
    Mahfood Haddad T; Hamdeh S; Kanmanthareddy A; Alla VM
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S209-S216. PubMed ID: 28017631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients.
    Hu YY; Dong NL; Qu Q; Zhao XF; Yang HJ
    Medicine (Baltimore); 2018 Oct; 97(43):e12931. PubMed ID: 30412101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications.
    Fernández-Mincone T; Contreras-Briceño F; Espinosa-Ramírez M; García-Valdés P; López-Fuenzalida A; Riquelme A; Arab JP; Cabrera D; Arrese M; Barrera F
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1141-1157. PubMed ID: 32811209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
    Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
    Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.